LensGen, Inc., an Irvine, Calif.-based ophthalmic medical device company, held the initial closing of a $10m of the $20m Bridge financing.
The round was led by Hoya Corporate Venture Capital Group, the corporate venture arm of Hoya Group and is part of a larger Series B Financing planned in early 2021 that will fund the company through approval of Juvene IOL pivotal FDA study.
The company also added James (Jim) Mazzo to its Board of Directors.
Led by Ramgopal Rao, CEO and Founder, LensGen is a clinical stage ophthalmic medical device company focused on restoring youthful vision to cataract and presbyopia patients via its Juvene® fluid-optic intraocular lens.
FinSMEs
20/08/2020